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OBJECTIVES: The role of tranexamic acid in upper gastrointestinal bleeding is 
controversial. We have therefore performed a systematic review and meta-analysis of 
randomized controlled trials to assess the effect of tranexamic acid in patients with upper 
gastrointestinal bleeding. 
METHODS: We searched PubMed, Embase, CINAHL, the Cochrane Central Register of 
Controlled Trials (CENTRAL), and relevant websites for randomised controlled trials 
investigating the effect of tranexamic acid published from inception to July 5, 2019. The 
primary outcome of interest was mortality. Estimates of effect were pooled with a random-
effects model. Quality of evidence was assessed using GRADE. This study is registered with 
PROSPERO (Registration number: CRD42018102516). 
RESULTS: The search strategy identified 1547 citations. Eleven trials were eligible for 
inclusion.  Of these, 10 trials comprising data for ???? patients compared tranexamic acid 
with placebo. There was a statistically significant effect of tranexamic acid in reducing 
mortality (RR 0.58, 95% CI 0.42 to 0.82); there was no significant heterogeneity between the 
studies (I2=0%, P=0.681). Pooled analysis of 6-7 studies that provided the relevant data 
showed no statistically significant difference between tranexamic acid and placebo with 
regard to the prevention of re-bleeding, surgical interventions, and the need for blood 
transfusions. The risk of adverse events with tranexamic acid was not different from placebo. 
The GRADE assessment rated the quality of the evidence in each outcome as ……..  
CONCLUSION: Tranexamic acid reduced risk of mortality compared with placebo. 















Upper gastrointestinal bleeding (UGIB) is defined as bleeding arising from any point in the 
gastrointestinal tract proximal to the suspensory ligament of the duodenum, the ligament of 
Treitz (1). It is a common emergency with mortality ranging from 14% in isolated bleeds and 
33% following hospitalization with other comorbidities (2). Mortality increases with 
increasing age, co-existing comorbidities, as well as, with re-bleeding episodes (2,3). Despite 
great advances made in the management of patients presenting with UGIB, mortality rates 
remain high (3,4). The main cause of death following UGIB is the resultant haemorrhagic 
shock (3). 
UGIB can be grouped into non-variceal bleeds, which includes bleeds from peptic ulcers and 
gastritis, or variceal bleeds, which includes UGIB associated with cirrhosis or liver disease 
(2). It usually presents with hematemesis, which is the vomiting of blood or blood clots, or 
the passage of melena or dark, tarry stools resulting from alteration of blood in the 
gastrointestinal tract. Therapeutic upper GI endoscopy is the standard treatment for 
significant upper GI bleed (3). However, in instances where this intervention is not readily 
available, or in cases where patients refuse endoscopic therapy, alternate forms of treatment, 
such as, the use of medical therapy to achieve haemostasis becomes highly relevant, and 
even, life-saving.  
Hyperfibrinolysis may contribute to some cases of UGIB (5). The possible beneficial effects 
of anti-fibrinolytic therapy for the treatment of UGIB has therefore been explored. The main 
anti-fibrinolytic therapies in clinical practice include tranexamic acid and aminocaproic acid 
(5). Tranexamic acid (TXA) is an anti-fibrinolytic agent which has gained widespread use in 
the last two decades in the reduction of bleeding in various trauma/surgical and obstetric 
haemorrhages. It has been shown to reduce the need for blood transfusion in many surgical 
patients (6,7). It is a synthetic derivative of the amino acid lysine and its mechanism of action 
is through reversible blockade of lysine binding sites on plasminogen molecules, thereby 
inhibiting the interaction of plasminogen and the heavy chain of plasmin with lysine residues 
on the surface of fibrin (6,8). It also directly inhibits plasmin non-competitively at high 
concentrations and thus, prevents the dissolution and degradation of fibrin clots by fibrin 
(8,9). 
However, the benefits of TXA in UGIB are controversial(3), and there is a need for further 
studies on this topic (10). A Cochrane systematic review published in 2014 found that 
tranexamic acid may have a beneficial effect on mortality but there were issues with the 
quality of the included trials (11). Following the publication of this systematic review, at least 
three new, randomized controlled trials have been published (12–14). In view of the recently 
published data, and the inconclusive nature of previous reports, we performed an up-to-date 







Search Strategy and study selection  
This systematic review and meta-analysis is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (The PRISMA statement) (15), 
and was registered at International Prospective Register of Systematic Reviews (PROSPERO; 
number CRD42018102516). We searched PubMed, Embase, CINAHL, and the Cochrane 
Central Register of Controlled Trials (CENTRAL) from inception to July 1, 2019. We also 
searched relevant websites (www.clinicaltrials.gov and www.controlled-trials.com) and 
reference lists of retrieved articles to try and identify additional citations that may have been 
missed through the electronic searches. Randomized controlled trials (RCT) that compared 
TXA use in UGIB to other treatment modalities for UGIB across all age groups were eligible 
for inclusion.  
Studies were identified with the following search terms: (upper gastrointestinal OR 
synonyms) AND (bleeding OR synonyms) AND (tranexamic acid OR synonyms). We 
included both medical subject headings (MeSH) and free text terms. There were no language 
restrictions. Two independent reviewers evaluated the titles and abstracts of papers to identify 
relevant studies. Articles identified were independently assessed by two reviewers using 
defined eligibility criteria. Disagreements between the reviewers were settled by consensus.  
Outcome Assessment  
The primary outcome was mortality. Secondary outcomes included duration of hospital stay, 
risk of rebleeding, the need for blood transfusion, the need for surgical interventions, and the 
occurrence of adverse events.  
Data extraction  
Data was extracted independently by two reviewers (ETB and IA) unto a Microsoft Excel 
spreadsheet using a pre-defined checklist. Extracted data included the following: risk of bias 
assessment, demographic information, methodology, intervention details, and reported 
outcomes.  The extracted data were compared and the differences were discussed and 
resolved by consensus. If the authors were unable to reach a consensus, a third author (AKA) 
arbitrated. The data was entered into the Cochrane Collaboration’s Review Manager 
(RevMan, version 5.3) for further processing and analysis.  
Assessment of risk of bias 
Two reviewers assessed the risk of bias in the selected studies in accordance with guidance 
published in the Cochrane handbook (16) Any disagreements were resolved by discussion 
and by inviting a third reviewer’s input. Records of methods used to generate the 
randomization schedule and conceal the allocation of treatment, whether or not blinding was 
implemented for participants, personnel, and outcome assessment, whether there was 
evidence of selective reporting or incomplete outcome data were assessed.  
Data synthesis and statistical analysis 
Dichotomous outcome data were pooled and the impact of tranexamic acid, compared with 
placebo was expressed as a relative risk (RR) of mortality, re-bleeding, need for surgical 
intervention, need for blood transfusion with 95% confidence intervals (CI). Adverse events 
data were also summarised with RRs and 95% CIs. All these analyses were decided a priori. 
The statistical test of heterogeneity was utilised to quantify the diversity in the results of the 
different studies and to assess whether the variation between the trials in the meta-analysis 
were due to true heterogeneity or as a result of chance. Heterogeneity was assessed using the 
I2 statistic, with a cut-off of ≥50% and the chi-squared test with a P<0.10 to define a 
significant degree of heterogeneity (17). Review Manager version 5.3 was used to generate 
the Forest plots of pooled RRs and 95% CI for all the outcomes of interest.  
For the primary outcome, mortality, the number needed to treat (NNT) for an additional 
beneficial outcome was calculated using the formula described in the Cochrane Handbook for 
Systematic Reviews of Interventions for computing number needed to treat from the results 
of a meta-analysis of risk ratios (18). This formula uses the pooled relative risk and an 
assumed control risk to compute the NNT. The calculation was further checked using an 
online calculator (Cates C. Visual Rx. Version 4, 2016. Available from 
http://www.nntonline.net. Accessed December 11, 2017). 
 
RESULTS  
The search strategy identified a total of 1540 citations, of which 63 met the criteria for full-
text review. A flow chart detailing the studies’ selection process is shown in Figure 1.  
Following full text review, we included 11 trials comprising data for 2076 patients (12–
14,19–26). 3 new RCTs were identified since the last review (12–14). In 10 of the included 
studies, patients were randomised to TXA (n=1071) or placebo (n=942).  In the eleventh 
study, patients were randomised to TXA or adrenaline. The age range of participants across 
the trials was 1 month old to 95 years. 
Tranexamic acid was administered via various routes in these trials. Biggs, Barer, Engqvist 
administered it via both intravenous and oral routes (21,23,25). It was administered solely 
intravenously by Von Holstein (24), and orally by Cormack (20) and Bergqvist (22). In Saidi 
2017, the tranexamic acid was administered via nasogastric tube (12), and either 
intravenously or via nasogastric tube topically by Bagnenko and Tavakoli (13,19). 
The risk of bias assessment in the trials is summarised in the “Risk of bias summary” (Figure 
2,3). We rated 5 trials as having adequate randomisation and allocation concealment 
(12,13,23,25,26). In 6 of the trials, participants were adequately blinded to the intervention 
and to outcome assessors (12,13,21,23,24,26). No trial was rated as having a high risk of bias 
for incomplete outcome data due to attrition. All but 1 trial were rated as low risk of bias for 
selective reporting (23), and no trial reported to be funded by industry.  
Based on GRADE, the overall quality of evidence was rated as ???? low or moderate for the 
main outcomes (appendix). 
Efficacy of Tranexamic acid for preventing deaths in UGIB 
Ten RCTs involving 2013 patients compared TXA with placebo in the treatment of UGIB 
(12,13,19–26). In a pooled analysis of all 10 trials, TXA significantly reduced risk of death 
(Figure 4). 53 of 1071 (4.9%) of patients who received TXA died compared to 9.4% (89/942) 
of patients who received placebo (RR 0.59, 95% CI 0.43-0.82, I2= 0%, p= 0.81). Sensitivity 
analysis conducted using a fixed effects model did not change the results (Figure 5). 
The NNT for this outcome was calculated using the maximum and minimum control risk of 
death amongst the included trials. In a population whose baseline risk of death (i.e. risk of 
death with placebo) was similar to the trial reported by XXX, (Ref) the NNT would be XX 
(95% CI X-Y).  In another population whose baseline risk was similar to the trial by 
XX,(Ref)  the NNT would be XX (95% CI X-Y).  
In the one study that was not included in the meta-analysis, there were no mortalities 
recorded in the TXA or placebo groups(14). 
Efficacy of Tranexamic acid for preventing re-bleeding in UGIB 
Eight of the trials included in the meta-analysis compared the number of re-bleeding events in 
the Tranexamic acid and Placebo groups (12,13,19,20,23–26). 
In total, there were 141 (15%) re-bleeding events in the 940 patients that received tranexamic 
acid, compared to 159 (7.3%) re-bleeding events in 810 patients allocated to receive placebo 
(RR of re-bleeding=0.79; 95% CI= 0.61-1.02; Figure 6). The was some heterogeneity 
between the studies, I2= 23%, P=0.24. 
Efficacy of Tranexamic acid for preventing surgical interventions in UGIB 
Nine trials compared the need for surgical interventions in the tranexamic acid and placebo 
groups (12,13,19,21–26). There were 93 (9.3%) surgical interventions in the 995 patients that 
received tranexamic acid, compared to 116 (13.4%) surgical interventions in the 868 patients 
allocated to receive placebo (RR of re-bleeding= 0.70; 95% CI= 0.43-1.13; Figure 7). The 
heterogeneity between the studies, I2= 60%; P=0.01. 
Efficacy of Tranexamic acid for preventing need for blood transfusion in UGIB 
A total of eight trials compared the frequency of blood transfusions between the tranexamic 
acid and placebo groups (13,20–26). Out of the 951 patients that received tranexamic acid, 
there were 385 (40.5%) blood transfusions, compared to 388 (47.8%) blood transfusions out 
of 812 patients allocated to receive placebo (RR of mortality=1.00; 95% CI= 0.93-1.08; 
Figure 8). There was no heterogeneity between studies (I2=0%, P=0.46) 
Efficacy of Tranexamic acid vs Placebo in preventing Thromboembolic events in UGIB 
Six trials assessed the development of thromboembolic events in both groups 
(12,13,19,20,24,25). There were 8 (1.4%) thromboembolic events in the 584 patients that 
received tranexamic acid, compared to 8 (1.8%) thromboembolic events out of 457 patients 
allocated to receive placebo (RR of mortality=0.89; 95% CI= 0.17-4.59; Figure 9). The 
heterogeneity, I2, between studies was 55%, P=0.11.  
Development of thrombophlebitis in Tranexamic acid vs Placebo in UGIB 
Two trials compared the development of thrombophlebitis in both groups (21,24).  5 (3%) out 
of a total of 175 patients that received tranexamic acid developed thrombophlebitis, 
compared to 2 (1%) out of 179 patients allocated to receive placebo (RR=2.02; 95% CI= 
0.44-9.26; Figure 10). There was no heterogeneity between studies, I2=0%, P=0.43) 
DISCUSSION  
Current UK and American guidelines on the treatment of UGIB do not recommend the use of 
tranexamic acid (27,28). This is because at the time of the publication of these guidelines, 
there were no conclusive evidence on the benefits of tranexamic acid in UGIB. A Cochrane 
meta-analysis published in 2014 found that tranexamic acid may have a beneficial effect on 
mortality (11), but there were issues with the quality of the included trials. Moreover, other 
outcomes such as rebleeding were not reduced. Following the publication of this meta-
analysis, 3 RCTs have been published on the topic (12–14). In light of these recently 
published data, we conducted an up-to-date systematic review and meta-analysis to evaluate 
the effect of TXA versus placebo or other interventions in patients with UGIB. By including 
data from the recent trials, the overall sample size is increased thereby improving the 
statistical power of our meta-analysis.  
 
The results of our meta-analysis show that TXA reduces the risk of death compared to 
placebo in patients with upper gastrointestinal bleeding. There was however no significant 
reduction in the risk of rebleeding or need for surgery. There was also no difference between 
the two groups with regard to risk of adverse events such as thromboembolic events. These 
results are consistent with the findings of the two most recent trials (12,13) and with the 
results of recent observational studies (TTT) that reported that TXA was associated with a 
lower risk of death. Results from a large trial which began in 2013, the ‘Haemorrhage 
alleviation with tranexamic acid- Intestinal system’ (HALT-IT) are still pending (29).  
 
Whilst the results of our analysis show that TXA is superior to placebo in patients with 
UGIB, the absolute benefit is modest with a number needed to treat ranging from X to Y 
patients to prevent one additional death. This may raise issues about the cost-effectiveness of 
TXA.  The NNT was calculated for two different baseline risks, the maximum and minimum 
control risk in the included trials (REF). Whilst the NNT is a clinically useful way to present 
results (REF), the limitations of a NNT calculated from pooled data must be considered.  We 
will suggest that readers apply the relative risk estimates from our meta-analysis to baseline 
risk data from their own populations to allow a more representative NNT to be calculated for 
their patients. 
 
In summary, this updated systematic review and meta-analysis has demonstrated that TXA 















































Records identified through database 
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Additional records identified through 
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(n =  5 ) 
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(n = 63) 
Records excluded 
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(n =  11 ) 
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interest = 2 
 
FIGURE 2   Summary of risk of bias of included studies: author’s judgement about each risk 
of bias item for each included study 
 
 
FIGURE 3. Summary of risk of bias of included studies: Graph review of author’s judgement 

























TABLE 1   Characteristics of Randomized Controlled Trials of Tranexamic Acid versus Placebo in UGIB  
 
Study, Country and Setting Criteria used to define UGIB Sample Size and Characteristics Tranexamic Acid Dose Used and duration of Therapy Control Used and Duration of Therapy Methodology
Cormack 1973, UK, 
Gloucestershire Royal 
Hospital    Presence of frank hematemesis 
150 participants of all ages 
grouped into age groups <45, 45-
60, >60 years. 49 males and 27 
females in TXA group and 51 
males and 23 females in Control 
group Tranexamic acid 1.5g 8 hourly for 7 days. Placebo tablets 8 hourly for 7 days
Double-blind RCT. Methods 
of randomization and 
concealment of allocation 
not stated. No concomitant 
medications given.
Biggs JC et al 1976, Australia, 
St Vincent Hospital
Patients presenting with 
haemorrhage (observed by medical 
officer) and requiring admission. 
Finding bleeding sites using 
endoscopy, barium studies, 
operations, and necroscopy
200 participants of unspecified 
ages. 73% males in the 
intervention group and 83% 
females in Control group
1g IV and 1g oral Tranexamic acid administered 8 
hourly for 48 hours, followed by 1g oral Tranexamic acid  
8hourly for 72hours
1g IV and 1g oral Placebo administered 8 
hourly for 48 hours, followed by 1g oral 
PLacebo 8hourly for 72hours
Double-blind RCT. Method 
of randomization and 
concealment of allocation 
not stated. No concomitant 
medications given
Bergqvist D 1980, Sweden, 
ICU
Patients with massive bleeding- 
hematemesis and /or melena with 
circulatory involvement 
50 participants with mean age 
range of 60.8(23-82) years in 
Tranxamic acid group and 57.6(26-
85) years in the control group. A 
total of 14 males and 7 females in 
the Tranexamic acid group and 20 
males and 2 females in the control 
gorup  
Oral solution of 2g Tranexamic acid administered via 
gastric tube every 4 hours within 1 hour of arriving at 
the ICU 
Oral solution of Placebo administered via 
gastric tube every 4 hours within 1 hour 
of arriving at the ICU 
Double-blind RCT. Method 
of randomization and 
concealment of allocation 
stated. Method of 
concealment not stated. 
Dextran given when needed.
Barer D et al 1983, UK, 
Medical wards of the 
Nottingham City and 
University hospitals Criteria not stated
775 patients with hematemesis or 
melena or both. No age limits.
1g of IV Tranexamic acid administered 6 hourly for 48 
hours, then orally every 6 hours for 5 days 
400mg of IV Ciimetidine or Placebo 
tablets administered 6 hourly for 
48hours, then orally every 6 hours for 5 
days 
Double-blind RCT. Method 
of randomization and 
concealment of allocation 
stated. Concomitant 
medications with the 
exception of H2 antagonists 
given when needed
Von Holsein et al 1987, 
Sweden, Department of 
Surgery - University of Lund 
and Central Hospital in 
Helsingborg
Presence of demonstrable benign 
gastric or duodenal lesion via 
endoscopy as the bleeding source 
154 patients. 18-87 9mean 62.4) in 
TXA group and 32-95 (mean 65.4) 
in control group. Male-to-female 
ratios in Tranexamic acid group is 
50:22 and in the control group 
58:24
1g of IV Tranexamic acid administered 4 hourly for 3 
days within 2 hours of admission
1g of Placebo administered 4 hourly for 3 
days within 2 hours of admission
Prospective Double-blind 
RCT. Method of 
randomisation and 
concealment of allocation 
stated. All patients received 
usual conservative 
medication.
Saidi H et al 2017, Iran, Hazrat 
Rasool General Hospital
Presence of endoscopically confirmed 
benign gastric or duodenal lesions in 
patients presenting with clinical signs 
of UGIB
131 patients of which 82 were 
males and 49 were females 
1g Tranexamic acid diluted in 250cc of saline solution 
administered via nasogastric tube 
Placebo (physiologic saline) 
administered via nasogastric tube 
Double-blind RCT. Method 
of randomisation stated. 
Method of concealment of 
allocation not stated. All 
patients received 
concomitant therapy
Tavacoli et al 2018, Iran, 
Rasoul-e-Akram Hospital in 
Tehran
History of hematochezia, melena and 
hematemesis. Also physical 
examination and/or lab test findings 
410 patients older than 18 years. 
274 males and 136 females
1g Tranexamic acid administered 6 hourly intravenously 
or topically via nasogastric tube and systemic 
Tranexamic acid  for 24 hours
Placebo (Sodium Chloride 0.9% ) 
administered for 24 hours
Double-blind RCT. Method 
of randomization and 
concealment of allocation 
stated. All patients received 
conventional medical 
therapy
Engqvist A 1979, Sweden, 
Sødersjukhuset
All patients treated for massive upper 
gastrointestinal haemorrhage (history 
of hematemesis and/or melena and 
with signs of circualtory 
embarassment) in the intensive care 
unit
149 patients included. 55 males 
and 21 females in the Tranexamic 
acid group and 61 males and 12 
females in the Placebo group
1g IV Tranexamic acid for 3 days followed by 1.5g orally 
4 times daily for 4 days
IV Placebo for 3 days followed by 1.5g 
orally 4 times daily for 4 days 
Double-blind RCT. Method 
of randomization and 
concealment of allocation 
stated. No concomitant 
medications given.
Rafeey M et al 2016, Iran, 
Children's Hospital-Tabriz
Presence of endoscopically confirmed 
gastric or duodenal bleeding 
63 children between ages of 1 
month to 15 years old. 30 girls and 
33 boys were included in the study
10ml of saline with 5ml of Tranexamic acid(500mg 
Tranexamic acid per vial) administered directly under 
endoscopic therapy by injecting into the submucosa of 
peptic ulver margins
10ml of saline with 5ml of Epinephrine 
(1/10,000) administered directly under 
endoscopic therapy by injecting into the 
submucosa of peptic ulcer margins
Methods of randomisation 
and concealment of 
allocation not stated. All 
patients received supportive 
medication of IV fluids and 
proton pump inhibitor drugs
Hawkey et al 2001, UK, 2 
hospitals in Nottingham Upper GI endoscopy of patients
414 male and female patients 
randomized of which 316 were 
endoscopically confirmed UGIB. 
Mean age of patients was 58.4 
(19.9%). 
Tranexamic acid 2g stat, followed by 1g four times daily 
alone or administered with Lansoprazole 60mg stat, 
then 30mg four times daily Placebo given four times dailly
Double-blind RCT, double 
dummy. Method of 
randomization stated. 
Method of concealment of 
allocation not stated. 
Patients received 
concomitant therapy
Bagnenko et al 2011, Russia, 
St Petersburg Research 
Institute Emergency care 47 patients 
IV Tranexamic acid 750mg (10mg/kg) per 200 ml of 
nat. solution 3 times a day for 1-3 days and via gastric 
tube 750mg of drug in 50ml of nat. solution 3 times 
daily in the first day. This was given in addition to 
conservative therapy
Only conservative therapy administered. 
Bolus IV Famotidine 40mg 4 times daily
RCT. Methods of 
randomization and 
allocation concealment not 
stated. Patients received 
concomitant therapy.
FIGURE 4.  Forest plot of randomized controlled trials of tranexamic acid vs placebo in preventing 
all-cause mortality in UGIB  
 
FIGURE 5.  Forest plot of randomized controlled trials of tranexamic acid vs placebo in preventing 
all-cause mortality in UGIB (Fixed effects Model) 
 
 
FIGURE 6.  Forest plot of randomized controlled of tranexamic acid vs placebo in preventing re-
bleeding in UGIB  
 
FIGURE 7. Forest plot of randomized controlled trials of tranexamic acid vs placebo in preventing 
the need for surgical interventions in UGIB  
 
FIGURE 8. Forest plot of randomized controlled trials reporting the frequency of blood transfusions 
in tranexamic acid vs placebo groups in UGIB  
 
 
FIGURE 9. Forest plot of randomized controlled trials reporting the development of 




FIGURE 10. Forest plot or randomized controlled trials reporting the development of 
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